• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Nonprofit research accelerator SAVE JON relaunches as Curable

Nonprofit research accelerator SAVE JON relaunches as Curable

July 6, 2016
CenterWatch Staff

SAVE JON, a nonprofit research accelerator that applies engineering approaches to medicine, is relaunching as Curable.

“Our research accelerator was originally named SAVE JON because our goal was to build a cure for primary sclerosing cholangitis (PSC) and save the life of my brother Jon, and fellow patients with PSC, many of whom will die without a liver transplant. We also wanted to make sure that we kept the patient at the very center of our research and development process,” said Curable CEO Lisa Boyette, M.D., Ph.D. “Those remain our mandates but we have now created an organizational blueprint that can be applied to other complex diseases and hard-to-solve problems. Our new name—Curable—better reflects that broader remit.”

SAVE JON was founded in 2014 by Dr. Boyette, her brother Jon, and Dietrich Stephan, Ph.D., chairman of the Department of Human Genetics at the University of Pittsburgh School of Public Health and former executive director of the Gene Partnership at Children’s Hospital Boston-Harvard Medical School.

“Developing therapies for life-threatening diseases is a complicated endeavor. But the reason it takes decades instead of years is—not that we don’t have the requisite tools or expertise—but we’re not working in the biggest, best teams we could be,” said Dr. Stephan. “Like Vice President Joe Biden and his Cancer Moonshot, we believe that collaboration and large-scale knowledge sharing are key ingredients for safely accelerating medical research. A patient focus is also essential.”

“Ultimately, a coordinated strategic plan and the resources to implement it rapidly are what make the difference. We are an engineering firm—problem solvers—and our expertise is in therapeutic and diagnostic development processes,” said Dr. Boyette.

There are an estimated 50,000 patients with PSC in the U.S. today. No one knows what causes this disease, and there are currently no effective medical therapies.

Within five years, Curable intends to have several new therapeutic options and an early diagnostic in phase II clinical trials for PSC.

To achieve its ambitious goals, Curable takes a highly-focused, strategic approach to tackling a disease. Bringing together all stakeholders—researchers, patients, clinicians, investors, and scientists—in a coordinated effort, and leveraging resources and expertise from academia, government, and industry, the Curable team is able to cross barriers and provide a platform where likeminded people can get together and do transformative work with the best tools available.

This interdisciplinary team oversees a multi-layered research platform, which includes new discovery to fill in knowledge gaps, and integrated analysis of existing datasets to identify connections that may have been missed previously. Curable is structured as a global hub to facilitate collaboration and coordination, data sharing, tissue and clinical record analyses, and the development of integrated disease models and accelerated therapeutic trials.

Curable now plans to harness cognitive computing and machine learning tools to find, compile, organize and network all known PSC data.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing